These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 4005128)

  • 21. Effect of controlled-release metoprolol on blood pressure and exercise heart rate in hypertension: a comparison with conventional tablets.
    Rydén L; Kristensson BE; Westergren G
    Eur J Clin Pharmacol; 1988; 33 Suppl():S33-7. PubMed ID: 3371392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration.
    Theeuwes F; Swanson DR; Guittard G; Ayer A; Khanna S
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):69S-76S. PubMed ID: 4005132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The antianginal efficacy and tolerability of controlled-release metoprolol once daily: a comparison with conventional metoprolol tablets twice daily.
    Egstrup K; Gundersen T; Härkönen R; Karlsson E; Lundgren B
    Eur J Clin Pharmacol; 1988; 33 Suppl():S45-9. PubMed ID: 3371394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK with a conventional slow release preparation.
    Oosterhuis B; Jonkman J; Zuiderwijk P; Sollie F
    J Clin Pharmacol; 1990 Feb; 30(S2):S33-8. PubMed ID: 2312777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of food on the absorption of metoprolol administered as an Oros drug delivery system to man.
    Lecaillon JB; Massias P; Schoeller JP; Abadie F
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):245S-249S. PubMed ID: 4005130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maximal exercise power after a single dose of metoprolol and of slow-release metoprolol.
    Folgering H; van Bussel M
    Eur J Clin Pharmacol; 1980 Oct; 18(3):225-9. PubMed ID: 7439241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications.
    Kendall MJ; Maxwell SR; Sandberg A; Westergren G
    Clin Pharmacokinet; 1991 Nov; 21(5):319-30. PubMed ID: 1773547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol.
    Kendall MJ; John VA; Quarterman CP; Welling PG
    Eur J Clin Pharmacol; 1980 Feb; 17(2):87-92. PubMed ID: 7371709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic and pharmacodynamic comparison of conventional and controlled release formulations of metoprolol [correction of motoprolol] in healthy Chinese subjects.
    Lee YT; Liau CS; Wong EC; Chen WJ; Chen MF; Chen CC
    Cardiovasc Drugs Ther; 1989 Aug; 3(4):529-33. PubMed ID: 2488104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing.
    Freestone S; Silas JH; Lennard MS; Ramsay LE
    Br J Clin Pharmacol; 1982 Nov; 14(5):713-8. PubMed ID: 7138751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Slow-release metoprolol in angina pectoris. A comparative study of a cardioselective beta-blocking drug, metoprolol, in ordinary and slow-release tablets (Durules) in the treatment of angina pectoris.
    Uusitalo AJ; Keyriläinen O
    Ann Clin Res; 1979 Oct; 11(5):199-204. PubMed ID: 44671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjects.
    Wieselgren I; Lundborg P; Sandberg A; Olofsson B; Bergstrand R
    J Clin Pharmacol; 1990 Feb; 30(S2):S28-32. PubMed ID: 2312776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic and pharmacodynamic properties of controlled release (CR/ZOK) metoprolol in healthy Oriental subjects: a comparison with conventional formulations of metoprolol and atenolol.
    Darmansjah I; Wong E; Setiawati A; Moeloek D; Irawati D; Siagian M; Muchtar A
    J Clin Pharmacol; 1990 Feb; 30(S2):S39-45. PubMed ID: 2312778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relationship between metoprolol plasma concentration and beta 1-blockade in healthy subjects: a study on conventional metoprolol and metoprolol CR/ZOK formulations.
    Abrahamsson B; Lücker P; Olofsson B; Regårdh CG; Sandberg A; Wieselgren I; Bergstrand R
    J Clin Pharmacol; 1990 Feb; 30(S2):S46-54. PubMed ID: 1968913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and tolerability of metoprolol OROS in hypertension treatment.
    Feliciano N; Kasarjian PH; McMillen JI; Grau KE; Kessler C; Stevelman HB; Hogan LB; Mroczek WJ; Goldstein RJ; Montoro R
    Am Heart J; 1990 Aug; 120(2):490-4. PubMed ID: 2382634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers.
    Lundborg P; Abrahamsson B; Wieselgren I; Walter M
    Eur J Clin Pharmacol; 1993; 45(2):161-3. PubMed ID: 8223839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of the beta 1-selectivity of conventional metoprolol and metoprolol CR during exercise in healthy volunteers.
    Akhlaghi S; Maxwell SR; Kendall MJ; Hughes B; Greenhaff P
    J Clin Pharm Ther; 1993 Aug; 18(4):259-66. PubMed ID: 8227233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of metoprolol OROS with antenolol in the treatment of effort angina pectoris: a randomized double-blind study.
    Floris B; Paoletti G; Pelizza L; Bertulla A; Motolese M
    Int J Clin Pharmacol Ther Toxicol; 1991 Apr; 29(4):139-43. PubMed ID: 1906434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma levels and negative chronotropic effect of metoprolol following single doses of a conventional and sustained-release formulation.
    Quaterman CP; Kendall MJ; Welling PG
    Eur J Clin Pharmacol; 1979 Mar; 15(2):97-103. PubMed ID: 436924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of two slow-release formulations of metoprolol with conventional metoprolol and atenolol in hypertensive patients.
    Silas JH; Freestone S; Lennard MS; Ramsay LE
    Br J Clin Pharmacol; 1985 Oct; 20(4):387-91. PubMed ID: 4074607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.